One Of Two French Ready To Participate in Clinical Trials

Armen Hareyan's picture

Nearly 46 percent of the French people have expressed willingness or desire to participate in a clinical trial shows a new poll. The researchers polled 2000 people and 46 percent of them said they will participate in clinical trials, revealing yet another little known secret about the French society. The research was conducted by Ifop and Lilly Institute.

The research shows very interesting things about the French attitude and the current situation of clinical trials in the country. It revealed that people's knowledge about the clinical trials is very limited and not everyone knows what trials involve. Despite this fact, almost one in two people said they will participate in a trial. The news comes on the backdrop of declining clinical trials in France.

According to those, interviewed by Ifop in late 2009 and early 2010, research and clinical trials should primarily involve the Cancer (cited by 3 out of 4 respondents), the Alzheimer's (36%), the AIDS (34%), and orphan diseases (22%). The cardiovascular diseases, which make up the leading cause of death in France, are cited by only 17% of French, the Diabetes by 9% and mental illness only by 7% of the responders, while the latter represent the leading cause of disability and the second reason for stopping work.


Three of four respondents believe that the clinical tests are well supervised and controlled by the government, but less than one in three (29%) know that children and adolescents can participate. Less than one in two French (47%) is aware that funding for this research is done by private funding and not public, and that the clinical trials are mostly practiced hospitals. Nearly 30% even think that participation in clinical trials are not always voluntary, which is wrong. The doctors may or can offer participation in the test, but the patients are free to accept or deny.

The respondents were aware of the high costs associated with clinical trials. In Europe it takes about 900 million euros to develop and manufacture a drug.

About 61 percent of the responders believe that these clinical trials are too risky for the patients. On the contrary, as pointed out by geriatrician Professor Bruno Vellas during the presentation of the survey, the studies show that people who participate in such studies are better monitored and see their condition deteriorate less quickly, even if they receives placebo instead of drug testing.

There is therefore a need for information and education. This was recognized by 72% of respondents. The encouraging part in this study is the high number of people, particularly men and older, are willing to participate in clinical trials, which can lead to more improved drugs and treatments for various types of diseases.